Literature DB >> 21844836

Low risk for hepatitis C seroconversion in methadone maintenance treatment.

Einat Peles1, Shaul Schreiber, Vera Rados, Miriam Adelson.   

Abstract

OBJECTIVES: To study the risk factors for seroconversion to hepatitis C virus (HCV) infection since admission to methadone maintenance treatment (MMT) and to characterize the seronegative admitted group.
METHODS: All 657 patients admitted to our MMT clinic in Tel Aviv, Israel, between 1993 and 2008 were prospectively followed up. Those who were HCV negative (n = 271) with >1 HCV tests (n = 207) were included for seroconversion analyses.
RESULTS: Proportions of ever drug injectors, benzodiazepine abuse, and former USSR immigrants were higher among HCV sera-positive versus sera-negative patients on admission to MMT. The incidence of HCV seroconversion in MMT was 2/100 person years [py] (25 seroconversions, 1133.9 py). Seroconversion rates were higher among 44 younger patients (<30 years: 9.6/100 vs 1.4/100 py, P < 0.0005), among 103 patients with positive urine results to benzodiazepines (3.6/100 vs 1/100 py, P = 0.005), among 118 patients who injected the drugs (3.9/100 vs 1/100 py, P = 0.003), and among 43 patients who dropped out and were readmitted to the MMT (4.3/100 vs 1.7/100 py, P = 0.04). There was a trend of higher seroconversion among 61 females (P = 0.1), among 62 patients with no children (P = 0.1), and among those having hepatitis B antigen (n = 7; P = 0.09). Variables that predicted seroconversion were drug injection, benzodiazepine abuse, and being younger at admission to MMT. Being a former USSR immigrant did not predict seroconversion.
CONCLUSIONS: The HCV seroconversion rate of patients in MMT is low, also, for former USSR immigrants. The predictors for seroconversion were only admission variables (younger age at admission to MMT, ever drug injector, and having positive urine to benzodiazepines at MMT admission). Specific intervention to eliminate seroconversion is needed for these high-risk groups.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844836     DOI: 10.1097/ADM.0b013e31820e13dd

Source DB:  PubMed          Journal:  J Addict Med        ISSN: 1932-0620            Impact factor:   3.702


  9 in total

1.  Benzodiazepine Use and Hepatitis C Seroconversion in a Cohort of Persons Who Inject Drugs.

Authors:  Paxton Bach; Geoffrey Walton; Kanna Hayashi; M-J Milloy; Huiru Dong; Thomas Kerr; Julio Montaner; Evan Wood
Journal:  Am J Public Health       Date:  2016-03-17       Impact factor: 9.308

2.  Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.

Authors:  Katelyn J Carey; Wei Huang; Benjamin P Linas; Judith I Tsui
Journal:  J Subst Abuse Treat       Date:  2016-02-13

Review 3.  Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.

Authors:  Lucy Platt; Silvia Minozzi; Jennifer Reed; Peter Vickerman; Holly Hagan; Clare French; Ashly Jordan; Louisa Degenhardt; Vivian Hope; Sharon Hutchinson; Lisa Maher; Norah Palmateer; Avril Taylor; Julie Bruneau; Matthew Hickman
Journal:  Cochrane Database Syst Rev       Date:  2017-09-18

4.  HCV and HIV infection among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Changsha and Wuhan, China.

Authors:  Xuyi Wang; Linxiang Tan; Yi Li; Yao Zhang; Dongyi Zhou; Tieqiao Liu; Wei Hao
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

5.  Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study.

Authors:  Xia Zou; Li Ling; Lei Zhang
Journal:  BMJ Open       Date:  2015-08-21       Impact factor: 2.692

6.  Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.

Authors:  Shiow-Ling Wu; Sheng-Chang Wang; Hsiao-Hui Tsou; Hsiang-Wei Kuo; Ing-Kang Ho; Sheng-Wen Liu; Ya-Ting Hsu; Yao-Sheng Chang; Yu-Li Liu
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

7.  Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period.

Authors:  Andrés Marco; Carlos Gallego; Joan A Caylà
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

8.  Epidemiology of hepatitis C virus infection among people receiving opioid substitution therapy (ECHO): study protocol.

Authors:  Lisa Strada; Bernd Schulte; Christiane Sybille Schmidt; Uwe Verthein; Peter Cremer-Schaeffer; Sabine Krückeberg; Jens Reimer
Journal:  BMC Infect Dis       Date:  2015-12-10       Impact factor: 3.090

9.  A Comparison of Medication for Opioid Use Disorder Treatment Strategies for Persons Who Inject Drugs With Invasive Bacterial and Fungal Infections.

Authors:  Laura R Marks; Satish Munigala; David K Warren; David B Liss; Stephen Y Liang; Evan S Schwarz; Michael J Durkin
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.